Elisa Andrini

5PUBLICATIONS
15CO-AUTHORS
Solid tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 28, 2025
Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives.

Anna Scognamiglio, Arianna Zappi, Elisa Andrini

|Feb 25, 2025
Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms.

Graziella Masciangelo, Davide Campana, Claudio Ricci

|Feb 24, 2023
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors.

Nicole Brighi, Giuseppe Lamberti, Elisa Andrini

|Nov 16, 2022
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.

Elisa Andrini, Alessandro Di Federico, Monia Sisi

|Jan 24, 2022
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.

Elisa Andrini, Giuseppe Lamberti, Francesca Mazzoni

Pageof 1

Frequent Collaborators

4 joint publications

Giuseppe Lamberti

3 joint publications

Davide Campana

2 joint publications

Andrea Lisotti

1 joint publications

Alessandro Di Federico